Is it safe to treat chronic hepatitis C patients with decompensated cirrhosis with PI-based DAAs?

Yu Jun Wong¹, Mindie H Nguyen²

Affiliations

¹ Department of Gastroenterology and Hepatology, Changi General Hospital, Singapore; Duke-NUS Medical School, Singapore. Electronic address: wongyujun1985@gmail.com.
² Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University Medical Center, Palo Alto, California, USA; Department of Epidemiology and Population Health, Stanford University Medical Center, Palo Alto, California, USA. Electronic address: mindiehn@stanford.edu.

PMID: 35074472
DOI: 10.1016/j.jhep.2021.12.037

Comment

Is it safe to treat chronic hepatitis C patients with decompensated cirrhosis with PI-based DAAs?

Yu Jun Wong et al. J Hepatol. 2022 Jul.

. 2022 Jul;77(1):257-258.

doi: 10.1016/j.jhep.2021.12.037. Epub 2022 Jan 21.

Authors

Yu Jun Wong¹, Mindie H Nguyen²

Affiliations

¹ Department of Gastroenterology and Hepatology, Changi General Hospital, Singapore; Duke-NUS Medical School, Singapore. Electronic address: wongyujun1985@gmail.com.
² Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University Medical Center, Palo Alto, California, USA; Department of Epidemiology and Population Health, Stanford University Medical Center, Palo Alto, California, USA. Electronic address: mindiehn@stanford.edu.

PMID: 35074472
DOI: 10.1016/j.jhep.2021.12.037

No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of interest WYJ: Invited speaker: Gilead. MHN: Research support: Pfizer, Enanta, Gilead, Exact Sciences, Vir Biotech, Helio Health, National Cancer Institute, Glycotest, B.K. Kee Foundation; Consulting and/or Advisory Board: Intercept, Exact Science, Gilead, GSK, Eli Lilly, Laboratory of Advanced Medicine, Janssen. Please refer to the accompanying ICMJE disclosure forms for further details.

Comment in

Reply to: "Is it safe to treat chronic hepatitis C patients with decompensated cirrhosis with PI-based DAAs?".
Torgersen J, Taddei TH, Lo Re V 3rd. Torgersen J, et al. J Hepatol. 2022 Jul;77(1):258-259. doi: 10.1016/j.jhep.2022.02.025. Epub 2022 Mar 10. J Hepatol. 2022. PMID: 35283213 No abstract available.

Comment on

Protease inhibitor-based direct-acting antivirals are associated with increased risk of aminotransferase elevations but not hepatic dysfunction or decompensation.
Torgersen J, Newcomb CW, Carbonari DM, Rentsch CT, Park LS, Mezochow A, Mehta RL, Buchwalder L, Tate JP, Bräu N, Bhattacharya D, Lim JK, Taddei TH, Justice AC, Lo Re V 3rd. Torgersen J, et al. J Hepatol. 2021 Dec;75(6):1312-1322. doi: 10.1016/j.jhep.2021.07.021. Epub 2021 Jul 29. J Hepatol. 2021. PMID: 34333102 Free PMC article.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Is it safe to treat chronic hepatitis C patients with decompensated cirrhosis with PI-based DAAs?

Affiliations

Is it safe to treat chronic hepatitis C patients with decompensated cirrhosis with PI-based DAAs?

Authors

Affiliations

Conflict of interest statement

Comment in

Comment on

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Research Materials

Miscellaneous